Steglatro Tablets

Description

Steglatro (ertugliflozin) is an oral medication used to treat type 2 diabetes. It belongs to a class of drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors, which work by helping the kidneys remove glucose from the bloodstream.

Dosage:
The recommended starting dose of Steglatro is 5 mg once daily. The dose may be increased to 15 mg once daily if additional glycemic control is needed.

Administration:
Steglatro should be taken orally once daily, with or without food.

Warnings:

• Steglatro can cause dehydration, which may lead to low blood pressure, kidney problems, or fainting. Patients should drink plenty of fluids while taking this medication.
• Steglatro can increase the risk of genital yeast infections, urinary tract infections, and yeast infections of the skin. Patients should contact their doctor if they experience any symptoms of these infections.
• Steglatro may increase the risk of lower limb amputations, especially in patients with a history of amputations or peripheral vascular disease.

Side Effects:
Common side effects of Steglatro include urinary tract infections, genital yeast infections, and changes in urination (such as increased frequency or urgency). Less common side effects include low blood sugar (especially when taken with other diabetes medications), dizziness, and nausea.

Contraindications:
Steglatro should not be used in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m²), end-stage renal disease, or on dialysis.

Drug Interactions:
Steglatro may interact with certain medications, including diuretics, insulin and insulin secretagogues, and medications that affect renal function.

Pregnancy and Lactation:
It is not known whether Steglatro can harm an unborn baby. Patients should talk to their doctor if they are pregnant or planning to become pregnant. It is also not known whether Steglatro passes into breast milk. Patients should talk to their doctor before breastfeeding while taking this medication.

Monitoring:
Patients taking Steglatro should be monitored regularly for changes in renal function, including changes in eGFR and urinary albumin-to-creatinine ratio. Blood pressure should also be monitored regularly, especially in patients with a history of hypertension or hypotension.